[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]

Ann Pathol. 2017 Feb;37(1):133-141. doi: 10.1016/j.annpat.2016.12.012. Epub 2017 Jan 31.
[Article in French]

Abstract

The role of the immune response in breast cancer is now well recognized and increasingly taken in account. The goal of this article is, in the first part, to underline its prognostic impact and to precise the immunosurvelliance, immunoselection and the immunosubversion concepts involved in the control and evasion of breast carcinoma. In the second part, therapeutic strategies for the restauration of anti-tumor immunity are developed. Vaccination strategies and checkpoints inhibitors blockade strategies are discussed as well as the immunogenic death linked to the conventional treatments of breast cancer.

Keywords: Breast cancer; Cancers du sein; Checkpoints inhibiteurs; Checkpoints inhibitors; Immunogenic death; Immunoselection; Immunosubversion; Immunosurveillance; Immunosélection; Mort immunogène.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm / immunology
  • B7-H1 Antigen / antagonists & inhibitors
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / therapy
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use
  • Combined Modality Therapy
  • Dendritic Cells / physiology
  • Female
  • Humans
  • Immunotherapy / methods*
  • Inflammation
  • Models, Immunological
  • Molecular Targeted Therapy
  • Monitoring, Immunologic
  • Mucin-1 / immunology
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / immunology
  • Phagocytosis
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Receptor, ErbB-2 / immunology
  • Tumor Escape / immunology
  • Tumor Microenvironment

Substances

  • Antigens, Neoplasm
  • B7-H1 Antigen
  • CD274 protein, human
  • Cancer Vaccines
  • MUC1 protein, human
  • Mucin-1
  • Neoplasm Proteins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • ERBB2 protein, human
  • Receptor, ErbB-2